Cingulate Inc. (CING)
NASDAQ: CING · Real-Time Price · USD
4.960
+0.200 (4.20%)
At close: Jun 26, 2026, 4:00 PM EDT
4.990
+0.030 (0.60%)
After-hours: Jun 26, 2026, 7:59 PM EDT
Cingulate Employees
Cingulate had 14 employees as of December 31, 2025. The number of employees increased by 1 or 7.69% compared to the previous year.
Employees
14
Change (1Y)
1
Growth (1Y)
7.69%
Revenue / Employee
n/a
Profits / Employee
-$1,993,523
Market Cap
65.85M
Employees Chart
Related Stocks
| Company Name | Employees |
|---|---|
| TScan Therapeutics | 139 |
| XBiotech | 87 |
| Acrivon Therapeutics | 76 |
| Seres Therapeutics | 66 |
| PMV Pharmaceuticals | 54 |
| Pliant Therapeutics | 49 |
| BeyondSpring | 44 |
| eXoZymes | 32 |
CING News
- 12 days ago - Cingulate issues patent by USPTO for CTx-1301 - TheFly
- 12 days ago - Cingulate Issued First U.S. Patent for Lead ADHD Asset CTx-1301 - GlobeNewsWire
- 23 days ago - Stonegate Capital Partners Updates Coverage on Cingulate Inc. (CING) 1Q26 - Newsfile Corp
- 24 days ago - Roth sees ‘major silver lining’ in Cingulate complete response letter - TheFly
- 25 days ago - Cingulate issued complete response letter for CTx-1301 from FDA - TheFly
- 26 days ago - US FDA declines to approve Cingulate's ADHD drug - Reuters
- 26 days ago - Cingulate Receives Complete Response Letter from FDA for CTx-1301 - GlobeNewsWire
- 4 weeks ago - Cingulate Proxy statement: Proxy filing - Filings